Opioid Tolerance Treatment Market (Drug - NMDA Antagonists (Ketamine, Dextromethorphan, Others), Alpha2-Adrenoceptor Agonists (Clonidine, Tizanidine, and Others); Type of Opioid Tolerance - Innate Tolerance, Acquired Tolerance; Route of Administration - Enteral, Parenteral; End use - Hospitals and Ambulatory Surgery Centers, Rehabilitation Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2030

Description

Global Opioid Tolerance Treatment – Overview:

Opioid treatment is massively noted in severe pain management and chronic cancer treatment. One of the reasons behind their extensive use is high efficacy. However, there are negative implication sometimes noted when these are used for a longer time. The effect in therapy reduces, and response to therapy becomes dull. Such patients require either higher doses or NMDA antagonists. Alpha2-adrenoceptor agonists are also put to work sometimes.

Some of the prominent factors leading to growth in the market are outlined below. These are molding the future of the market in a major way.

Drug abuse is gaining a firm foothold across countries and communities. Some of the regions that are facing a menace in terms of opium use are the countries falling in proximity to the Golden Crescent and the Golden Triangle – regions known for illicit opium production in the Asia Pacific region. Authorities and medical community is trying to fight this through research and development, and development of better therapeutics, paving way for growth in the market.

A robust pipeline exists in the market for tolerance treatment and a number of clinical trials are underway. This ensures growth for the global opioid tolerance treatment market over the forecast period. The use in healthcare will be a major factor of growth.

Global Opioid Tolerance Treatment Market - Snapshot

Opioids are effective analgesics prescribed to people with chronic cancer and severe pain. These opioids are generally used for short period of time. If these opioids are prescribed or taken for a longer period of time or more frequent daily doses, they create opioid tolerance in patients and hence, analgesia or desired therapeutic response is not received. In such conditions, higher doses of opioids are required to treating patients.

Opioid tolerant patients can be treated with other treatment options for opioid tolerance such as NMDA antagonists and alpha2-adrenoceptor agonists. These drugs provide the required therapeutic response to opioid tolerant patients or to treat opioid tolerance.

The global opioid tolerance treatment market was valued at around US $1,500 Mn in 2018. It is anticipated to expand at a CAGR of around 3.5% from 2019 to 2027. The alpha2-adrenoceptor agonists segment dominates the global opioid tolerance treatment market in terms of value and is expected to continue this trend during the forecast period.

The opioid tolerance treatment market is expanding at a significant pace due to rise in consumption of opioids for medical & non-medical purposes and rise in number of opioid prescriptions for therapeutic purpose, which leads opioid tolerance if taken for a long duration of time.

Additionally, ongoing clinical trials, various researches going on for opioid tolerant treatment by different research institutes & companies and growing drug abuse, drug overdose cases are some of the major factors responsible for the growth of opioid tolerance treatment market. 

The opioid tolerance treatment market has been segmented based on drug, type of opioid tolerance, route of administration, end-user, and region.

On the basis of drug, the global opioid tolerance treatment market has been divided into NMDA antagonists, alpha2-adrenoceptor agonists, and others.

The NMDA antagonists segment has been sub-segmented into ketamine, dextromethorphan, and others. The alpha2-adrenoceptor agonists segment is sub-divided into clonidine, tizanidine, and others.

The alpha2-adrenoceptor agonists segment dominated the global opioid tolerance treatment market during the forecast period and is expected to continue this trend during the forecast period owing to relatively fewer side effects and better efficacy to treat opioid tolerance.

Based on type of opioid tolerance, the global opioid tolerance treatment market has been bifurcated into innate tolerance and acquired tolerance. The acquired tolerance segment dominated the global opioid tolerance treatment market in 2018. The segment is anticipated to expand at a considerable CAGR during the forecast period owing to increase of drug dose & quantity and long term use of opioids.

In terms of route of administration, the global opioid tolerance treatment market has been categorized into enteral, parenteral, and others. The parenteral segment dominated the global opioid tolerance treatment market. Faster onset of action and high bioavailability are some factors driving this segment.

Based on end-user, the global opioid tolerance treatment market has been classified into hospitals & ASCs, rehabilitation centers, and others. The hospitals & ASCs segment dominated the global opioid tolerance treatment market due to higher number of patient admissions for cancer, chronic pain and better facilities available at these settings. 

opioid tolerance treatment market

In terms of region, the global opioid tolerance treatment market has been split into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

North America dominated the global opioid tolerance treatment market in 2018 due to higher number of opioid prescriptions dispensed, high opioid consumptions, and well-established health care infrastructure in the region.

The opioid tolerance treatment market in Asia Pacific is expanding at a considerable CAGR during the forecast period due to large cancer patient pool, increase in health care expenditure, and high opioid consumption in the region. 

Key players operating in the global opioid tolerance treatment market include

  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Otsuka Pharmaceutical Co. Ltd.
  • Johnson & Johnson Services
  • Aurobindo Pharma
  • Pfizer Inc.
  • Acorda Therapeutics, Inc.
  • Zydus Cadila

Global Opioid Tolerance Treatment Market: Key Segments

  • The opioid tolerance treatment market has been categorized based on drug, type of opioid tolerance, route of administration, end-user, and region.
  • In terms of drug, the global market has been segregated into NMDA antagonists, alph2-adrenoceptor agonists, and others. The NMDA antagonists segment has been sub-segmented into ketamine, dextromethorphan, and others. Similarly, the alpha2-adrenoceptor agonists segment has been divided into clonidine, tizanidine, and others.
  • In terms of type of opioid tolerance, the global opioid tolerance treatment market has been bifurcated into innate tolerance and acquired tolerance.
  • Based on route of administration, the global market has been segmented into enteral, parenteral, and others.
  • In terms of end-user, the global opioid tolerance treatment market has been classified into hospitals & Ambulatory surgery centers, rehabilitation centers, and others.
  • Each of the segments has been analyzed in detail for market trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The report provides current and future market size for each segment and sub-segments for the period from 2017 to 2027 in terms of revenue valued in US $ Mn, considering 2018 as the base year. The compound annual growth rate has been provided for each segment and market for the period of 2019 to 2027 with market size estimations. 

The global opioid tolerance treatment market has been segmented as follows:

Drug

  • NMDA Antagonists
  • Ketamine
  • Dextromethorphan
  • Others (including Guaifenisin)
  • Alpha2-adrenoceptor Agonists
  • Clonidine
  • Tizanidne
  • Others(including Lofexidine)
  • Others (including Endothelin Receptor Antagonists, NSAIDs, Opioid Combinations, and Multimodal Pain Management Drugs)

Opioid Tolerance

  • Innate Tolerance
  • Acquired Tolerance

Route of Administration

  • Enteral
  • Parenteral
  • Others (including Transdermal Route, Patches, and Cartons of Patches) 

End-user

  • Hospitals & ASCs
  • Rehabilitation Centers
  • Others (including Home Care Settings and Research Institutes) 

Region

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of the Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

TABLE OF CONTENT

1. Preface
      1.1. Market Definition and Scope
      1.2. Market Segmentation
      1.3. Key Research Objectives
      1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Opioid Tolerance Treatment Market

4. Market Overview
      4.1. Introduction
              4.1.1. Opioid Tolerance Definition
              4.1.2. Industry Evolutions / Developments
      4.2. Overview
      4.3. Market Dynamics
              4.3.1. Drivers
              4.3.2. Restraints
              4.3.3. Opportunities
      4.4. Global Opioid Tolerance Treatment Market Analysis and Forecasts, 2017–2030
              4.4.1. Market Revenue Projections (US$ Mn)
      4.5. Porter’s Five Force Analysis

5. Market Outlook
      5.1.Key Mergers & Acquisitions 
      5.2.Pipeline Analysis
      5.3.Opioids Side Effects-an Overview
      5.4.Overview of Opioid Tolerance and Epidemiology

6. Global Opioid Tolerance Treatment Market Analysis and Forecasts, by Drug 
      6.1. Introduction & Definition
      6.2. Key Findings / Developments
      6.3. Market Value Forecast, by Drug, 2017–2030
              6.3.1. NMDA Antagonists
                        6.3.1.1. Ketamine
                        6.3.1.2. Dextromethorphan
                        6.3.1.3. Others
              6.3.2. Alpha2-adrenoceptor Agonists
                        6.3.2.1. Clonidine
                        6.3.2.2. Tizanidine
                        6.3.2.3. Others
              6.3.3. Others
      6.4. Market Attractiveness by Drug 

7. Global Opioid Tolerance Treatment Market Analysis and Forecasts, by Type of Opioid Tolerance 
      7.1. Introduction & Definition
      7.2. Key Findings / Developments
      7.3. Market Value Forecast, by Type of Opioid Tolerance, 2017–2030
              7.3.1. Innate Tolerance
              7.3.2. Acquired Tolerance
      7.4. Market Attractiveness, by Type of Opioid Tolerance 

8. Global Opioid Tolerance Treatment Market Analysis and Forecasts, by Route of Administration 
      8.1. Introduction & Definition
      8.2. Key Findings / Developments
      8.3. Market Value Forecast, by Route of Administration, 2017–2030
              8.3.1. Enteral
              8.3.2. Parenteral
              8.3.3. Others
      8.4. Market Attractiveness by Route of Administration 

9. Global Opioid Tolerance Treatment Market Analysis and Forecasts, by End-user 
      9.1. Introduction & Definition
      9.2. Key Findings / Developments
      9.3. Market Value Forecast, by End-user, 2017–2030
              9.3.1. Hospitals 
              9.3.2. Rehabilitation Centers
              9.3.3. Others
      9.4. Market Attractiveness by End-user 

10. Global Opioid Tolerance Treatment Market Analysis and Forecasts, by Region
      10.1. Key Findings
      10.2. Market Value Forecast, by Region
              10.2.1. North America 
              10.2.2. Europe 
              10.2.3. Asia Pacific 
              10.2.4. Latin America 
              10.2.5. Middle East & Africa 
      10.3. Market Attractiveness by Country/Region

11. North America Opioid Tolerance Treatment Market Analysis and Forecast
      11.1. Introduction
              11.1.1. Key Findings
      11.2. Market Value Forecast, by Drug, 2017–2030
              11.2.1. NMDA Antagonists
                        11.2.1.1. Ketamine
                        11.2.1.2. Dextromethorphan
                        11.2.1.3. Others
              11.2.2. Alpha2-adrenoceptor Agonists
                        11.2.2.1. Clonidine
                        11.2.2.2. Tizanidine
                        11.2.2.3. Others
              11.2.3. Others
      11.3. Market Value Forecast, by Type of Opioid Tolerance, 2017–2030
              11.3.1. Innate Tolerance
              11.3.2. Acquired Tolerance
      11.4. Market Value Forecast, by Route of Administration, 2017–2030
              11.4.1. Enteral
              11.4.2. Parenteral
              11.4.3. Others
      11.5. Market Value Forecast, by End-user, 2017–2030
              11.5.1. Hospitals 
              11.5.2. Rehabilitation Centers
              11.5.3. Others
      11.6. Market Value Forecast, by Country/Sub-region, 2017–2030
              11.6.1. U.S.
              11.6.2. Canada
      11.7. Market Attractiveness Analysis 
              11.7.1. by Drug 
              11.7.2. by Type of Opioid Tolerance 
              11.7.3. by Route of Administration 
              11.7.4. by End-user 
              11.7.5. by Country/Sub-region

12. Europe Opioid Tolerance Treatment Market Analysis and Forecast
      12.1. Introduction
              12.1.1. Key Findings
      12.2. Market Value Forecast, by Drug, 2017–2030
              12.2.1. NMDA Antagonists
                        12.2.1.1. Ketamine
                        12.2.1.2. Dextromethorphan
                        12.2.1.3. Others
              12.2.2. Alpha2-adrenoceptor Agonists
                        12.2.2.1. Clonidine
                        12.2.2.2. Tizanidine
                        12.2.2.3. Others
              12.2.3. Others
      12.3. Market Value Forecast, by Type of Opioid Tolerance, 2017–2030
              12.3.1. Innate Tolerance
              12.3.2. Acquired Tolerance
      12.4. Market Value Forecast, by Route of Administration, 2017–2030
              12.4.1. Enteral
                            12.4.2. Parenteral
              12.4.3. Others
      12.5. Market Value Forecast, by End-user, 2017–2030
              12.5.1. Hospitals 
              12.5.2. Rehabilitation Centers
              12.5.3. Others
      12.6.Market Value Forecast, by Country/Sub-region, 2017–2030
              12.6.1. Germany
              12.6.2. U.K.
              12.6.3. France
              12.6.4. Spain
              12.6.5. Italy
              12.6.6. Rest of Europe
      12.7. Market Attractiveness Analysis 
              12.7.1. by Drug 
              12.7.2. by Type of Opioid Tolerance 
              12.7.3. by Route of Administration 
              12.7.4. by End-user 
              12.7.5. by Country/Sub-region

13. Asia Pacific Opioid Tolerance Treatment Market Analysis and Forecast
      13.1. Introduction
              13.1.1. Key Findings
      13.2. Market Value Forecast, by Drug, 2017–2030
              13.2.1. NMDA Antagonists
                        13.2.1.1. Ketamine
                        13.2.1.2. Dextromethorphan
                        13.2.1.3. Others
              13.2.2. Alpha2-adrenoceptor Agonists
                        13.2.2.1. Clonidine
                        13.2.2.2. Tizanidine
                        13.2.2.3. Others
              13.2.3. Others
      13.3. Market Value Forecast, by Type of Opioid Tolerance, 2017–2030
              13.3.1. Innate Tolerance
              13.3.2. Acquired Tolerance
      13.4. Market Value Forecast, by Route of Administration, 2017–2030
              13.4.1. Enteral
              13.4.2. Parenteral
              13.4.3. Others
      13.5. Market Value Forecast, by End-user, 2017–2030
              13.5.1. Hospitals 
              13.5.2. Rehabilitation Centers
              13.5.3. Others
      13.6. Market Value Forecast, by Country/Sub-region, 2017–2030
              13.6.1. China
              13.6.2. Japan
              13.6.3. India
              13.6.4. Australia & New Zealand
              13.6.5. Rest of Asia Pacific
      13.7. Market Attractiveness Analysis 
              13.7.1. by Drug 
              13.7.2. by Type of Opioid Tolerance 
              13.7.3. by Route of Administration 
              13.7.4. by End-user 
              13.7.5. by Country/Sub-region

14. Latin America Opioid Tolerance Treatment Market Analysis and Forecast
      14.1. Introduction
              14.1.1. Key Findings
      14.2. Market Value Forecast, by Drug, 2017–2030
              14.2.1. NMDA Antagonists
                        14.2.1.1. Ketamine
                        14.2.1.2. Dextromethorphan
                        14.2.1.3. Others
              14.2.2. Alpha2-adrenoceptor Agonists
                        14.2.2.1. Clonidine
                        14.2.2.2. Tizanidine
                        14.2.2.3. Others
              14.2.3. Others
      14.3. Market Value Forecast, by Type of Opioid Tolerance, 2017–2030
              14.3.1. Innate Tolerance
              14.3.2. Acquired Tolerance
      14.4. Market Value Forecast, by Route of Administration, 2017–2030
              14.4.1. Enteral
              14.4.2. Parenteral
              14.4.3. Others
      14.5. Market Value Forecast, by End-user, 2017–2030
              14.5.1. Hospitals 
              14.5.2. Rehabilitation Centers
              14.5.3. Others
      14.6. Market Value Forecast, by Country/Sub-region, 2017–2030
              14.6.1. Brazil
              14.6.2. Mexico
              14.6.3. Rest of Latin America
      14.7. Market Attractiveness Analysis 
              14.7.1. by Drug 
              14.7.2. by Type of Opioid Tolerance 
              14.7.3. by Route of Administration 
              14.7.4. by End-user 
              14.7.5. by Country/Sub-region

15. Middle East & Africa Opioid Tolerance Treatment Market Analysis and Forecast
      15.1. Introduction
              15.1.1. Key Findings
      15.2. Market Value Forecast, by Drug, 2017–2030
              15.2.1. NMDA Antagonists
                        15.2.1.1. Ketamine
                        15.2.1.2. Dextromethorphan
                        15.2.1.3. Others
              15.2.2. Alpha2-adrenoceptor Agonists
                        15.2.2.1. Clonidine
                        15.2.2.2. Tizanidine
                        15.2.2.3. Others
              15.2.3. Others
      15.3. Market Value Forecast, by Type of Opioid Tolerance, 2017–2030
              15.3.1. Innate Tolerance
              15.3.2. Acquired Tolerance
      15.4. Market Value Forecast, by Route of Administration, 2017–2030
              15.4.1. Enteral
              15.4.2. Parenteral
              15.4.3. Others
      15.5. Market Value Forecast, by End-user, 2017–2030
              15.5.1. Hospitals 
              15.5.2. Rehabilitation Centers
              15.5.3. Others
      15.6. Market Value Forecast, by Country/Sub-region, 2017–2030
              15.6.1. GCC Countries
              15.6.2. South Africa
              15.6.3. Rest of Middle East & Africa
      15.7. Market Attractiveness Analysis 
              15.7.1. by Drug 
              15.7.2. by Type of Opioid Tolerance 
              15.7.3. by Route of Administration 
              15.7.4. by End-user 
              15.7.5. by Country/Sub-region

16. Competition Landscape
      16.1. Market Player – Competition Matrix (by Tier and Size of companies)
      16.2. Competitive Business Strategies
      16.3. Company Profiles
              16.3.1. Boehringer Ingelheim International GmbH
              16.3.2. GlaxoSmithKline plc
              16.3.3. Teva Pharmaceutical Industries Ltd.
              16.3.4. Mylan N.V.
              16.3.5. Otsuka Pharmaceutical Co., Ltd.
              16.3.6. Johnson & Johnson Services, Inc.
              16.3.7. Aurobindo Pharma
              16.3.8. Pfizer Inc.
              16.3.9. ACORDA THERAPEUTICS
              16.3.10. Zydus Cadil

Delivery Format : EXCEL/Data Pack

Choose License Type

Checkout Inquiry Sample